New shares of Bioretec Ltd subscribed with option rights have been registered with the trade register
Bioretec Ltd Company announcement 22 October 2021 at 12.30 p.m.
An aggregate number of 125,487 new shares of Bioretec Ltd have been subscribed for with option rights under option program 2021-1. The new shares have today on 22 October 2021 been registered with the trade register maintained by the Finnish Patent and Registration Office. The total subscription price of EUR 125.63 will be recorded in Bioretec's reserve of invested unrestricted equity, and the company's share capital remains unchanged.
Following the registration of the new shares, the total number of registered shares in Bioretec is 14,111,858.
The new shares will be issued in the book-entry system on or about 22 October 2021. The new shares will confer shareholder rights in the company as of their registration on the investors' book-entry accounts. Trading in the new shares is expected to commence on Nasdaq First North Growth Market Finland on or about 26 October 2021.
No new shares may be subscribed for under the option program 2021-1.
Further enquiries
Timo Lehtonen, CEO, tel. +358 50 433 8493
Johanna Salko, CFO, tel. +358 40 754 8172
Certified Adviser:
Nordic Certified Adviser AB, tel. +46 70 551 67 29
Information about Bioretec
Bioretec’s mission is to promote healing after trauma or orthopedic surgery, building on a unique understanding of bioresorbable medical implants that act as scaffolds for tissue growth and eliminate the need for removal surgery of the implants. Bioretec's bioresorbable polymer implants are used worldwide and the company intends to launch a new series of innovative implants based on a unique bioresorbable metallic alloy, RemeOsTM. The RemeOsTM product line is designed to meet the unmet medical need of demanding load-bearing fixations, and to facilitate a seamless transition for surgeons from conventional titanium implants. Better healing – Better life.